Alliance of translational research centres established to accelerate global drug development
The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network to ultimately improve the rate at which academic research is translated into new medicines.
New CD3 website online
Check out the new CD3 website!
European Investment Fund and KU Leuven invest 16 million euro in CD3
KU Leuven and the European Investment Fund (EIF) are investing an additional 16 million euro in CD3, thereby increasing the total capital of CD3 to 24 million euro.
License agreement with Pfizer for the development of new anti-HIV drugs
In 2010, KU Leuven entered into a license agreement with Pfizer. The license agreement grants Pfizer exclusive and sublicenseable worldwide rights to further develop and commercialise KU Leuven’s compounds with a new mechanism of action for the potential treatment of individuals infected with HIV, the virus that causes AIDS.
Arcarios announces successful completion of a seed-financing round
Biotech company Arcarios announces successful completion of a seed-financing round. An international syndicate of investors has funded the company to further develop its lead programs in the field of osteoarthritis and bone diseases.